サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：末梢血管血栓管理インターベンションの世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374797

末梢血管血栓管理インターベンションの世界市場 - 2023年～2030年

Global Peripheral Vascular Clot Management Interventions Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
末梢血管血栓管理インターベンションの世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

血栓を早期に発見し治療することで、脳卒中や血管疾患による死亡率を大幅に減少させることができます。血液凝固（凝固）は、血管が傷ついたときに過剰な出血を防ぐ重要なプロセスです。血小板（血液細胞の一種）と血漿（血液の液体部分）中のタンパク質が協力して、傷の上に血栓を形成して出血を止めます。

さらに、世界の末梢血管血栓管理インターベンション市場は、心血管疾患の世界の発生率の上昇、血栓管理デバイスの技術的発展、そのような最先端技術の継続的な開発など、さまざまな要因によって牽引されており、Abbott Laboratories、Edward Lifesciences Corporation、Medtronic Inc、Teleflex Medicalなどの主要企業が予測期間中にこの市場を成長させると思われます。

ダイナミクス

血管疾患の有病率の上昇

血管疾患の有病率の上昇は、予測期間中に市場が成長するための重要な要因の1つです。末梢動脈疾患（PAD）や深部静脈血栓症（DVT）のような疾患の有病率は増加傾向にあり、その主な原因は喫煙、肥満、座りがちな行動などのライフスタイル要因です。このため、血栓管理の介入が必要とされています。

例えば、米国疾病予防管理センターの最新ファクトシートによると、深部静脈血栓症（DVT）または肺塞栓症（PE）の正確な患者数は不明ですが、米国では毎年90万人が罹患している可能性があります。

老年人口の増加

高齢者は、運動能力の低下、慢性的な健康状態（高血圧、糖尿病、心臓病など）、服用している薬などの加齢に関連した要因により、血栓発症のリスクが高くなることが多いです。例えば、世界保健機関（WHO）の推計によると、2050年までに60歳以上の人口は世界で21億人になり、2020年の10億人から増加します。

加えて、60歳以上の人口が深部静脈血栓症（体内の深部静脈に血栓が形成される）の独立した危険因子であることが、複数の情報源や調査によって示されています。したがって、高齢者人口の増加と高齢者における血栓症の負担は、血栓管理デバイスの需要を生み出し、分析期間中の市場成長を促進すると予想されます。

デバイスの高コスト

末梢血管血栓管理介入デバイスは高価であるため、一部の患者にとってはアクセスの障壁となり得る。これらのデバイスのコストが高いのは、手技の複雑さとデバイスに使用される高度な技術によるものです。

例えば、血管内動脈瘤修復ステントグラフトのコストは非常に高く、予測期間中の市場成長を妨げる抑制要因となり得る。動脈瘤に関連した後続治療の入院費用の中央値は2万2,023米ドル（IQR,1万3,177米ドル～4万7,752米ドル）であったのに対し、動脈瘤に関連しない後続治療費用の中央値は1万9,007米ドル（IQR,8,708米ドル～3万3,301米ドル）でした。

本レポートの詳細サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 血管疾患の有病率の上昇
      • 老年人口の増加
    • 抑制要因
      • デバイスの高コスト
    • 機会
      • 新興市場での製品上市の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 デバイスタイプ別

  • カテーテル
  • 血管内動脈瘤修復ステントグラフト
  • 下大静脈フィルター
  • プラーク修正デバイス
  • 血行動態改善デバイス
  • その他の末梢血管用デバイス

第8章 適応症別

  • 深部静脈血栓症（DVT）
  • 肺動脈塞栓症

第9章 エンドユーザー別

  • 病院
  • 外来手術センター
  • 専門クリニック

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Edward Lifesciences Corporation.
  • Medtronic Inc.
  • Teleflex Medical.
  • Boston Scientific Corporation.
  • Biotronik
  • Merit
  • B. Braun SE
  • Terumo Corporation
  • Penumbra Inc

第13章 付録

目次
Product Code: MD7213

Overview

Early detection and treatment of blood clots can significantly reduce the death rate due to stroke and vascular diseases. Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Platelets (a type of blood cell) and proteins in your plasma (the liquid part of the blood) work together to stop the bleeding by forming a clot over the injury.

Furthermore, the global peripheral vascular clot management interventions market is driven by various factors like the rising global incidence of cardiovascular diseases, technological advancements in clot management devices, continuous development of such cutting-edge technologies and others that will help this market to grow during the forecast period having significant key players like Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc, Teleflex Medical and others.

Dynamics

Rising Prevalence of Vascular Diseases

The rise in the prevalence of vascular diseases is one of the key factors that helps the market to grow during the forecast period. The prevalence of conditions like peripheral artery disease (PAD) and deep vein thrombosis (DVT) has been on the rise, primarily due to lifestyle factors like smoking, obesity, and sedentary behaviour. This drives the need for clot management interventions.

For instance, according to the Centers for Disease Control and Prevention updated factsheet The precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States.

Increase in the Incidence of Geriatric Population

Older individuals often face a higher risk of developing blood clots due to age-related factors such as reduced mobility, chronic health conditions (e.g., hypertension, diabetes, heart disease), and medications they may be taking. For instance, The World Health Organization (WHO) estimates that by 2050, there will be 2.1 billion people worldwide who are 60 years of age or older, up from 1 billion in 2020.

In addition, several sources and research show that the population aged 60 years or more is the foremost independent risk factor for deep vein thrombosis (when a blood clot forms in one or more of the deep veins in the body). Thus, the increasing geriatric population coupled with the burden of thrombosis among them is expected to create demand for clot management devices, thereby driving the market growth over the analysis period.

High Cost of Devices

Peripheral vascular clot management intervention devices can be costly, which can be a barrier to access for some patients. The high cost of these devices is due to the complexity of the procedures and the advanced technology used in the devices.

For instance, endovascular aneurysm repair stent grafts costs are very high which can be a restraint factor that hamper the market growth during the forecast period. The median cost of hospitalization for aneurysm-related subsequent intervention was $22,023 (IQR, $13,177-$47,752), compared with a median non-aneurysm-related subsequent intervention cost of $19,007 (IQR, $8708-$33,301).

For more details on this report Request for sample

Segment Analysis

The global peripheral vascular clot management interventions market is segmented based on device type, indication, end-user and region.

The Catheters Segment From the Device Type Segment Accounted For Approximately 41.7% of Peripheral Vascular Clot Management Interventions Share

The catheters segment from the device type segment accounted for 41.7% and it is expected to be dominated during the forecast period. The catheters are used to send clot-dissolving medicine to the DVT. This can help break up the clot or else the healthcare provider might use small tools to help break up the clot.

Catheter-directed thrombolysis treats vascular blockages and improves blood flow by dissolving abnormal blood clots. A blood clot, or thrombus, can block off blood supply to certain parts of the body and cause serious damage. Catheter-directed thrombolysis uses X-ray imaging and a catheter to guide special medication or a medical device to the site of a blood clot to dissolve the blockage.

For instance, in September 2021 Boston Scientific Corporation stated an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the factors like novel treatment, new device launches, FDA Clearance, advanced healthcare infrastructure, Robust Healthcare Spending and other factors that help this region to grow during the forecast period.

For instance, in February 2023 Woodland Heights Medical Center is the first in the Lufkin/Nacogdoches area to utilize a new treatment for pulmonary embolism and deep vein thrombosis. It is the first mechanical thrombectomy device FDA indicated and purpose-built for this treatment.

Deep vein thrombosis (DVT) typically occurs when a blood clot forms in the legs and pulmonary embolism (PE) occurs when a part of the clot breaks off, travels through the bloodstream and causes a blockage of blood flow to the lungs. The blockage of blood flow results in right heart strain as the right ventricle is unable to push blood past the clot. In severe cases, right heart failure may occur leading to a fatal event.

Moreover, in January 2023 Penumbra, Inc. a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's novel Lightning Intelligent Aspiration technology, now with dual clot detection algorithms.

Competitive Landscape

The major global players in the market include: Abbott Laboratories., Edward Lifesciences Corporation., Medtronic Inc., Teleflex Medical, Boston Scientific Corporation., Biotronik, Merit, B. Braun SE, Terumo Corporation, Penumbra Inc and among others.

COVID-19 Impact Analysis

During the early phases of the pandemic, many conventional peripheral vascular clot management treatments were postponed or cancelled as healthcare resources were redirected to treat COVID-19 patients. As a result, procedure numbers and the market for associated medical devices and medications declined in the short term.

Also, the mysterious clots in COVID-19 patients may be due to the binding of the SARS-CoV-2 spike protein with the ACE2 receptor in blood vessel endothelial cells. This interaction has caused vasoconstriction and activation of the intrinsic coagulation pathway, leading to the formation of blood clots. The pathogenesis of SARS-CoV-2 and the role of ACE2 in RAS are also considered.

Key Developments

  • In March 2023 SMT stated that it has been selected as the exclusive distributor of Penumbra's peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Under the terms of the agreement, SMT will provide healthcare providers with Penumbra's latest Indigo System portfolio, including CATTM RX, which recently received India CDSCO (Central Drug Standard Control Organization) approval, and Lightning technologies, upon regulatory approval, to address conditions such as coronary thrombosis, venous thrombosis, arterial thrombosis and pulmonary embolism.
  • In March 2021 Penumbra, Inc., a global healthcare company focused on innovative therapies, stated U.S. commercial availability of the Indigo System Lightning 7. Lightning 7 expands Penumbra's offering of the Indigo Aspiration System with Intelligent Aspiration for mechanical thrombectomy and is designed for single-session arterial thrombus removal.

Why Purchase the Report?

  • To visualize the global peripheral vascular clot management interventions market segmentation based on device type, indication, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global peripheral vascular clot management interventions market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global peripheral vascular clot management interventions market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Vascular Diseases
      • 4.1.1.2. Increase in the Incidence of Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Devices
    • 4.1.3. Opportunity
      • 4.1.3.1. Rise in the Product Launches in Emerging Markets
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type
  • 7.2. Catheters*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Endovascular Aneurysm Repair Stent Grafts
  • 7.4. Inferior Vena Cava Filters
  • 7.5. Plaque Modification Devices
  • 7.6. Hemodynamic Flow Alteration Device
  • 7.7. Other Peripheral Vascular Devices

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Deep Vein Thrombosis (DVT) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pulmonary Artery Embolism

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Specialty Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Edward Lifesciences Corporation.
  • 12.3. Medtronic Inc.
  • 12.4. Teleflex Medical.
  • 12.5. Boston Scientific Corporation.
  • 12.6. Biotronik
  • 12.7. Merit
  • 12.8. B. Braun SE
  • 12.9. Terumo Corporation
  • 12.10. Penumbra Inc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us